Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S
Go back to Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S| TONIX PHARM HLDG (NASDAQ: TNXP) | Delayed: 13.14 -0.23 (1.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.37 | 52 Week High | $7.95 | |||
| Open | $13.30 | 52 Week Low | $0.40 | |||
| Day High | $13.33 | P/E | N/A | |||
| Day Low | $12.99 | EPS | $-5.33 | |||
| Volume | 252,492 | |||||
